VTT and GE Healthcare developing novel biomarkers to predict Alzheimer’s disease
Scientists from VTT Technical Research Centre of Finland in collaboration with the University of Eastern Finland have recently discovered a serum biochemical signature which predicts progression to Alzheimer’s disease months or even years before the first symptoms of the disease occur. The goal of the new collaboration between VTT and GE Healthcare is to validate this biomarker in a large patient cohort as well as to discover novel biomarker candidates.
Early detection of prodromal AD is vital both for assessing the efficacy of potential AD therapeutic agents as well as new disease modifying therapies are most likely to be effective when initiated during the early stages of disease. The elucidation of early metabolic pathways associated with progression to Alzheimer’s disease may also help in identifying new therapeutic avenues.
In 2010 GE Healthcare entered into “biosignatures initiative” alliance with Janssen Pharmaceutica N.V. (Janssen) to develop diagnostic biosignatures for pre-symptomatic identification of AD. As part of this programme, VTT will apply serum metabolite profiling to validate their recently discovered biochemical signature, as well as to discover novel biomarker candidates predictive of progression to AD.
VTT’s research professor Matej Orešič said: “We are excited about the prospect of collaborating with GE Healthcare to accelerate its research programs and to further develop our biomarker towards a clinical assay applicable in healthcare setting. VTT has over the past years built unique metabolomics and systems biology platforms and acquired vast amount of knowledge on metabolic profiles and pathways in human health and disease, which allow us to identify disease-specific biochemical signatures and pathways. We believe that integration of metabolomics into the GE’s and Janssen’s biosignatures initiative will lead to better tools for early detection of AD and may also lead to better therapeutic options.”
Other news from the department science
Most read news
More news from our other portals
Last viewed contents
Epigenomics AG Receives Allowances for Key Patents in Europe - Patents cover biomarker mPITX2 for prostate and breast cancer indications
Measuring chemistry: local fingerprint of hydrogen bonding captured in experiments
Analytik Jena aquires majority of distributor in Romania - Analytik Jena took over 70% of the company shares of a Romanian company based on a cash-share deal.
Nature-inspired coatings could power tiny chemistry labs for medical testing and more - Researchers develop polymer coating that enables low surface tension liquids to be transported over distances 15 times longer than currently possible, without losing any of the liquid
BOSELLO now fully part of the ZEISS Group - BOSELLO HIGH TECHNOLOGY becomes Carl Zeiss X-ray Technologies Srl
Destination China as Level Sensors and Transmitters Markets Make a Comeback - Increased investments in manufacturing and greater automated production to fuel demand in emerging economies
New study supports use of PCA3-based test for prostate cancer diagnosis - European commercialization in progress
European multi-center study suggests PCA3 test more accurate for prostate cancer
Vibrations key to efficiency of green fluorescent protein - Charting femtosecond energy flow could aid redesign of molecules to improve light capture
Entire T-cell receptor repertoire sequenced revealing extensive and unshared diversity
Chiral Technologies Europe Acquires ChromTech Ltd. of U.K.
